Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Лечение частично платиночувствительного рецидива рака яичников
Лечение частично платиночувствительного рецидива рака яичников
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Комбинация платины и таксанового препарата является стандартом химиотерапии первой линии больных раком яичников. Выбор препаратов для проведения терапии рецидива зависит от продолжительности бесплатинового интервала. Пациентки, у которых продолжительность бесплатинового интервала варьирует от 6 до 12 мес, классифицируются как частично платиночувствительные. Основываясь на результатах клинических рандомизированных исследований, для лечения таких больных специалисты рекомендуют применять комбинации препаратов платины с гемцитабином или паклитакселом. Третьим препаратом, комбинации которого с карбоплатином активно изучаются у частично платиночувствительных больных, является пегилированный липосомальный доксорубицин (ПЛД). Однако в некоторых случаях частично платиночувствительным больным может быть назначена монотерапия такими препаратами, как карбоплатин или ПЛД; также пациентка может быть включена в протокол соответствующего исследования. Увеличение продолжительности бесплатинового интервала путем проведения монотерапии с использованием неплатинового препарата (например, ПЛД) при первом рецидиве теоретически может быть целесообразным. Тем не менее данная терапевтическая тактика требует оценки в рамках проспективных рандомизированных исследований.
Полный текст
Список литературы
1. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: three-year results [see comments]. J Natl Cancer Inst 2000; 92 (9): 699–708.
2. Peerez-Loepez ME, Curiel T, Goеmez JG, Jorge M. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 2006; 18: 611–7.
3. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099–106.
4. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol/Hematol doi:10.1016/j.critrevonc.2007.04.004.
5. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005; 15: 209–16.
6. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reintroduction after taxane in patients with platinumrefractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584–8.
7. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl. 5): 20–8.
8. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004; 10: 7439–49.
9. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93.
10. ten Bokkel Huinink W, Lane SR, Ross GAon behalf of the International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100–3.
11. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312–22.
12. Gordon AN, Tonda M, Sun S, Rackoff Won behalf of the Doxil Study 30–49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1–8.
13. O'Byrne KJ, Bliss P, Graham JD et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxanenaive relapsed ovarian cancer (abstract 808). Proc Am Soc Clin Oncol 2002; 21: 203a.
14. Ferrandine G, Lorusso D, Pignata S et al. A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxirubicin (PLD) in progressive/recurrent ovarian cancer (OC), 2007 ASCO meeting proceedings part I. J Clin Oncol 2007; 18S: LBA5506.
15. Gordon AN, Teitelbaum A. Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer (abstract and poster). Eur J Cancer Suppl 2003; 1: S51.
16. Pignata S, Odicino F, Scambia G et al. Extending the platinum-free interval (PFI) with a non-platinum therapy in platinum (P)-sensitive recurrent ovarian cancer (OC): results from the SOCRATES retrospective study, 2006 ASCO annual meeting proceedings part I. J Clin Oncol 2006; 15 (18S): 5093.
17. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, and the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699–707.
18. Ferrero J-M, Weber B, Geay J-F et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263–8.
19. Alberts DS, Liu PY, Wilczynski S et al. Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200, 2007 ASCO meeting proceedings part I. J Clin Oncol 2007; 25 (18S): 5551.
20. Sessa C, DeBrand F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867–74.
21. Andreopoulou E, Gaiotti D, Kim E et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with longterm maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18: 716–21.
22. Collins Y, Lele S. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc 2005; 97: 1414–6.
23. Gifford G, Paul J, Vasey PA et al. Group obotSGCT. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420–6.
24. Plumb JA, Strathdee G, Sludden J et al. Reversal of drug resistance in human tumor xenografts by 20-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039–44.
25. Lee C, Appleton K, Plumb J et al. A Phase I trial of decitabine in combination with carboplatin, both given 4 weekly by i.v. injection in patients with advanced solid tumours. Proc Am Soc Clin Oncol 2004; 23: 128.
2. Peerez-Loepez ME, Curiel T, Goеmez JG, Jorge M. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 2006; 18: 611–7.
3. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099–106.
4. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol/Hematol doi:10.1016/j.critrevonc.2007.04.004.
5. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005; 15: 209–16.
6. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reintroduction after taxane in patients with platinumrefractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584–8.
7. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl. 5): 20–8.
8. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004; 10: 7439–49.
9. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93.
10. ten Bokkel Huinink W, Lane SR, Ross GAon behalf of the International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100–3.
11. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312–22.
12. Gordon AN, Tonda M, Sun S, Rackoff Won behalf of the Doxil Study 30–49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1–8.
13. O'Byrne KJ, Bliss P, Graham JD et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxanenaive relapsed ovarian cancer (abstract 808). Proc Am Soc Clin Oncol 2002; 21: 203a.
14. Ferrandine G, Lorusso D, Pignata S et al. A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxirubicin (PLD) in progressive/recurrent ovarian cancer (OC), 2007 ASCO meeting proceedings part I. J Clin Oncol 2007; 18S: LBA5506.
15. Gordon AN, Teitelbaum A. Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer (abstract and poster). Eur J Cancer Suppl 2003; 1: S51.
16. Pignata S, Odicino F, Scambia G et al. Extending the platinum-free interval (PFI) with a non-platinum therapy in platinum (P)-sensitive recurrent ovarian cancer (OC): results from the SOCRATES retrospective study, 2006 ASCO annual meeting proceedings part I. J Clin Oncol 2006; 15 (18S): 5093.
17. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, and the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699–707.
18. Ferrero J-M, Weber B, Geay J-F et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263–8.
19. Alberts DS, Liu PY, Wilczynski S et al. Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200, 2007 ASCO meeting proceedings part I. J Clin Oncol 2007; 25 (18S): 5551.
20. Sessa C, DeBrand F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867–74.
21. Andreopoulou E, Gaiotti D, Kim E et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with longterm maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18: 716–21.
22. Collins Y, Lele S. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc 2005; 97: 1414–6.
23. Gifford G, Paul J, Vasey PA et al. Group obotSGCT. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420–6.
24. Plumb JA, Strathdee G, Sludden J et al. Reversal of drug resistance in human tumor xenografts by 20-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039–44.
25. Lee C, Appleton K, Plumb J et al. A Phase I trial of decitabine in combination with carboplatin, both given 4 weekly by i.v. injection in patients with advanced solid tumours. Proc Am Soc Clin Oncol 2004; 23: 128.
Авторы
Stanley B.Kaye
Великобритания
Великобритания
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.